Mobilisation of haemopoietic stem cells in teriparatide-treated patients

Intern Med J. 2015 Aug;45(8):872-6. doi: 10.1111/imj.12830.

Abstract

Parathyroid hormone (PTH) is the predominant regulator of calcium/phosphate homeostasis in the human body. Beside this classical function, preclinical and clinical studies indicated a relevant role for PTH in mobilisation of bone marrow-derived cells into peripheral blood. In addition, recombinant PTH (teriparatide) was recently approved for the treatment of severe osteoporosis. Therefore, it was the aim of the present study to investigate the dynamics of haemopoietic stem cells and corresponding in peripheral blood of 13 patients with osteoporosis during treatment with teriparatide. We were able to show that administration of teriparatide is sufficient to mobilise haemopoietic stem cells into the bloodstream accompanied by an alteration of mobilising cytokines. In conclusion, teriparatide might be a useful tool in the context of stem cell mobilisation.

Keywords: haemopoietic stem cell; osteoporosis; teriparatide.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Aged
  • Aged, 80 and over
  • Bone Density Conservation Agents / therapeutic use*
  • Female
  • Hematopoietic Stem Cell Mobilization / methods*
  • Hematopoietic Stem Cells / physiology*
  • Humans
  • Male
  • Middle Aged
  • Osteoporosis / drug therapy*
  • Prospective Studies
  • Teriparatide / therapeutic use*

Substances

  • Bone Density Conservation Agents
  • Teriparatide